NEW YORK, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended September 30, 2025 (“Third Quarter 2025”). Unless otherwise noted, percentage and other changes are relative to the three months ended September 30, 2024 (“Third Quarter 2024”). Highlights Third Quarter 2025 revenue of $626.4 million, down 2% year-over-yearThird Quarter 2025 net loss of $49.5 million, or $0.28 per shareThird Quarter ...

ROSEVILLE, Minn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- At its recent board meeting, the Board of Directors of Hawkins, Inc. (Nasdaq: HWKN) declared a quarterly cash dividend of $0.19 per share, payable November 28, 2025, to shareholders of record at the close of business on November 14, 2025. Hawkins has consistently paid out a dividend since 1985. About Hawkins, Inc. Hawkins, Inc. was founded in 1938 and is a leading water treatment and specialty ingredients company that formulates, manufactures, distributes ...

Core Insights - Prenetics Global Limited has published a comprehensive manifesto detailing its strategic vision, combining healthcare growth with Bitcoin treasury management [2][3] - The company's flagship brand, IM8, achieved $100 million in annual recurring revenue within 11 months of launch, marking the fastest growth in the supplement industry [3][6] - Prenetics projects revenue of $180 to $200 million for FY 2026 [3][6] Healthcare Engine (IM8) - IM8 is co-founded by David Beckham and supported by tennis champion Aryna Sabalenka, contributing to its rapid growth [3][6] - The brand's success generates substantial cash flows that facilitate sophisticated Bitcoin treasury management [5] Bitcoin Treasury Engine - As of October 29, 2025, Prenetics holds 277 BTC and employs a disciplined strategy of acquiring 1 BTC daily [4][7] - This Bitcoin treasury is described as a "fortress of value," providing financial resilience and appreciation potential [4] Synergy Between Healthcare and Bitcoin - The integration of IM8's growth with Bitcoin treasury management creates a virtuous cycle, enhancing both healthcare expansion and financial appreciation [5]

DALLAS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- United States Lime & Minerals, Inc. (NASDAQ: USLM) today reported third quarter 2025 results: The Company’s revenues in the third quarter 2025 were $102.0 million, compared to $89.4 million in the third quarter 2024, an increase of $12.6 million, or 14.1%. For the first nine months 2025, the Company’s revenues were $284.8 million, compared to $237.7 million in the first nine months 2024, an increase of $47.1 million, or 19.8%. The increases in revenues in the third ...

Core Viewpoint - Teekay Corporation Ltd. has provided an update on its financial performance for the three months ending September 30, 2025, indicating ongoing operations in the marine transportation sector [1]. Company Overview - Teekay is a prominent provider of international crude oil marine transportation and related marine services, operating through its controlling interest in Teekay Tankers Ltd. [2] - Teekay Tankers manages approximately 55 conventional tankers and other marine assets, including vessels operated for the Australian Government, showcasing its extensive operational capacity [2]. - The company has a global presence with offices in 8 countries and around 2,200 seagoing and shore-based employees, serving leading energy companies worldwide [2]. Stock Information - Teekay's common stock is traded on the New York Stock Exchange under the symbol "TK" [3].

Core Viewpoint - Nobel Resources Corp. has announced a new financing initiative, the LIFE Offering, aiming to raise between $1.5 million and $2.5 million through the sale of units priced at $0.05 each, with a closing date anticipated around November 17, 2025 [1][8]. Group 1: Offering Details - The LIFE Offering will consist of a minimum of 30,000,000 units and a maximum of 50,000,000 units, with each unit comprising one common share and one-half of a common share purchase warrant [1][2]. - Each warrant will allow the holder to purchase one share at a price of $0.06 for a period of 24 months following the closing date, with a 70-day waiting period before exercise [2]. - The company will pay a cash commission of 7% on the gross proceeds to the agents and issue broker warrants equal to 7% of the total units sold [3]. Group 2: Regulatory and Compliance - The LIFE Offering will be available to purchasers in all Canadian provinces except Québec, under the listed issuer financing exemption [4]. - The securities from the LIFE Offering are expected to be freely tradable under Canadian securities legislation if sold to Canadian residents [4]. Group 3: Additional Offerings - In addition to the LIFE Offering, the company plans a concurrent non-brokered private placement of up to 20,000,000 units [5]. - Participation from certain insiders in the non-brokered offering will be classified as a related party transaction, with the company relying on exemptions from formal valuation requirements [6]. Group 4: Use of Proceeds - The net proceeds from both offerings will be allocated towards exploration work on the company's mineral properties in Chile, as well as for general corporate and working capital purposes [7]. Group 5: Closing and Approval - The offerings are subject to necessary approvals, including that of the TSX Venture Exchange, and are expected to close on or before 45 days from the announcement date [8]. Group 6: Company Overview - Nobel Resources is a Canadian resource company focused on identifying and developing mineral projects, backed by a team with a strong exploration success record [12].

Core Insights - NewtekOne, Inc. reported significant year-over-year growth in diluted earnings per share (EPS), with increases of approximately 49% for the third quarter of 2025 and 22% year-to-date [5][9]. Financial Performance - For the three months ended September 30, 2025, basic and diluted EPS were $0.68 and $0.67, respectively, compared to $0.45 for the same period in 2024, reflecting year-over-year increases of 51% and 49% [5]. - For the nine months ended September 30, 2025, basic and diluted EPS were $1.57 and $1.54, respectively, compared to $1.26 for the same period in 2024, reflecting year-over-year increases of 25% and 22% [5]. - Total revenue for the third quarter of 2025 was $74.9 million, up 19.3% from $62.8 million in the third quarter of 2024 [5]. - Year-to-date total revenue was $211.5 million, an increase of 16.0% from $182.3 million in the same period of 2024 [5]. Balance Sheet Highlights - Book value per common share at the end of the third quarter of 2025 was $11.72, up 16.4% year-over-year [5]. - Tangible book value per common share was $11.22, reflecting a year-over-year increase of 25.6% [5]. - Total assets as of September 30, 2025, were $2.399 billion, compared to $2.059 billion as of December 31, 2024 [19]. Capital and Funding - The company raised $30 million of Common Equity Tier 1 (CET1) capital and increased Tier 1 capital by issuing $50 million of depositary shares [6]. - Newtek Merchant Solutions refinanced and upsized its borrowing facility with a new $95 million financing solution [6]. Loan Originations - The company originated $104 million in Alternative Loan Program (ALP) loans in the third quarter of 2025, compared to $66 million in the same quarter of 2024 [6]. - SBA 7(a) loans originated in the third quarter of 2025 totaled $187 million, down from $243 million in the same quarter of 2024 [6]. Operational Efficiency - The efficiency ratio improved to 56.3% for the third quarter of 2025, compared to 61.8% for the same quarter in 2024 [5]. - Return on average assets (ROAA) was 3.06% for the third quarter of 2025, while return on average tangible common equity (ROTCE) was 23.7% [5][9]. Strategic Developments - The company has transitioned from a business development company to a financial holding company, enhancing its ability to provide business and financial solutions [9]. - NewtekOne aims to leverage technology to operate as a digital bank, having opened over 21,000 bank accounts digitally [9].

NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Adamas Trust, Inc. (Nasdaq: ADAM) (“Adamas,” the “Company,” “we,” “our” or “us”) today reported results for the three and nine months ended September 30, 2025. Summary of Third Quarter 2025: (dollar amounts in thousands, except per share data) Net income attributable to Company's common stockholders$32,702 Net income attributable to Company's common stockholders per share (basic)$0.36 Earnings available for distribution attributable to Company's common stockholder ...

Core Insights - Dianthus Therapeutics presented positive data from the Phase 2 MaGic trial for claseprubart in generalized Myasthenia Gravis (gMG), indicating potential for 300mg/2mL Q4W dosing [1][3][4] - A Phase 3 gMG trial is planned to start in 2026, including QMG ≥10 screening criteria and two treatment arms: 300mg/2mL Q2W and 300mg/2mL Q4W, compared to placebo [1][4][7] - New preclinical data suggest efficacy benefits of upstream (active C1s) versus downstream (C5) complement inhibition [1][5] Company Overview - Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases [3][9] - The company aims to build a neuromuscular franchise with claseprubart and plans to initiate a Phase 3 trial in gMG in 2026 [7][9] Clinical Data Highlights - The Phase 2 MaGic trial showed a robust decline in MG-ADL of -2.5 points at week 4 in the open-label extension, with a QMG score reduction of -3.2 points for placebo patients who received only two doses of claseprubart [5][6] - A subgroup analysis indicated a 3-point difference in MG-ADL treatment effect for patients with a QMG score ≥10 at baseline receiving 300mg/2mL Q2W [5][6] Future Outlook - The company is motivated to proceed to Phase 3 trials based on the impressive Phase 2 data and encouraging post hoc analyses [4][7] - Upcoming trials include the interim responder analysis of the Phase 3 CAPTIVATE trial in Chronic Inflammatory Demyelinating Polyneuropathy in the second half of 2026 and top-line data from the Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy [7]

Core Insights - Cumulus Media's Westwood One has appointed Armen Williams as Executive Director of Westwood One Sports 24/7 Programming, effective November 3, 2025, to lead the development of new sports content [1][2] - Williams brings over 20 years of audio programming experience and has previously held leadership roles at Audacy, Bonneville, and Townsquare [3] - The new role will involve overseeing sports talk content, technical operations, social media strategy, and brand management, with a focus on creating engaging on-air programming [2][4] Company Overview - Cumulus Media is an audio-first media company reaching a quarter billion people monthly through 395 radio stations across 84 markets and the largest audio network in America, Westwood One [5] - The company provides a variety of programming, including sports, news, talk, and entertainment, and offers advertisers a range of services including digital marketing and live event experiences [5] Westwood One Sports - Westwood One Sports is the exclusive network radio partner to the NFL since 1987 and covers major sports events including NCAA Basketball, U.S. Soccer, and The Masters [6] - The network aims to enhance its sports programming under Williams' leadership, focusing on delivering high-quality content to listeners [4][6]